Cardiac resynchronization therapy indications: Difference between revisions
Jump to navigation
Jump to search
| (34 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiac resynchronization therapy}} | {{Cardiac resynchronization therapy}} | ||
{{CMG}}; {{AOEIC}} Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com], {{HP}} | {{CMG}}; {{AOEIC}} {{Sara.Zand}} Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com], {{HP}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Indications== | ==Indications== | ||
== | ==2021 ESC Guideline for [[Cardiac Resynchronization Therapy]] implantation== | ||
<span style="font-size:85%">'''Abbreviations:''' | |||
{| | '''AF:''' [[Atrial fibrillation]]; | ||
'''A-V:''' [[Atrio-ventricular]]; | |||
'''CRT:''' [[Cardiac resynchronization therapy]] ; | |||
'''HFrEF:''' [[Heart failure with reduced ejection fraction]]; | |||
'''ICD:''' [[Implantable cardioverter-defibrillato]]; | |||
'''LBBB:'''[[Left bundle branch block]]; | |||
'''LVEF:''' [[Left ventricular ejection fraction]]; | |||
''' NYHA:'''[[ New York Heart Association]]; | |||
'''RV:''' = [[Right ventricular]] | |||
</span> | |||
<br> | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | |||
|- | |- | ||
| | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF;" align=center |'''Recommendations for cardiac resynchronization therapy implantation in patients with heart failure''' | ||
|- | |- | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | ''' ([[ 2021 ESC guidelines classification scheme|Class I, Level of Evidence A]]):''' | ||
|- | |- | ||
| | |style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left| | ||
❑ [[CRT]] is recommended for symptomatic [[patients]] with [[HF]] in [[sinus rhythm]] with a [[QRS duration]] ≥150 ms and [[LBBB]] [[QRS]] morphology and with [[LVEF]] ≤35% | |||
despite [[optimal medical therapy]] in order to improve [[symptoms]] and reduce [[morbidity]] and [[mortality]]<br> | |||
❑ [[CRT]] rather than [[RV pacing]] is recommended for [[patients]] with [[HFrEF]] regardless of [[NYHA]] class or [[QRS]] duration who have an indication for [[ventricular]] pacing for [[high degree AV block]] in order to reduce[[ morbidity]] including [[AF]] | |||
|- | |- | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | ''' ([[ 2021 ESC guidelines classification scheme|Class IIa, Level of Evidence B]]):''' | ||
|- | |- | ||
| | |style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left| | ||
❑ [[CRT]] should be considered for symptomatic [[patients]] with [[HF]] in [[sinus rhythm]] with a [[QRS]] duration ≥150 ms and non-[[LBBB]] [[QRS]] morphology and | |||
with [[LVEF]] ≤35% despite [[OMT]] in order to improve [[symptoms]] and reduce [[morbidity]] and [[mortality]]<br> | |||
❑ [[CRT]] should be considered for symptomatic [[patients]] with [[HF]] in [[sinus rhythm]] with a [[QRS]] duration of130-149 ms and [[LBBB]] [[QRS]] morphology and with [[LVEF]] ≤35% despite [[optimal medical therapy]] in order to improve symptoms and reduce [[morbidity]] and [[mortality]]<br> | |||
❑ [[Patients]] with an [[LVEF]] ≤35% who have received a conventional [[pacemaker]] or an [[ICD]] and subsequently develop worsening [[HF]] despite [[optimal medical therapy]] and who have a significant proportion of [[RV pacing]] should be considered for upgrade to [[CRT]]<br> | |||
|- | |- | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''([[ESC guidelines classification scheme|Class IIb, Level of Evidence B]]) :''' | ||
|- | |- | ||
| | |style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left| | ||
❑ [[CRT]] may be considered for [[symptomatic]] [[patients]] with [[HF]] in [[sinus rhythm]] with a [[QRS]] duration of 130-149 ms and non-[[LBBB]] [[QRS]] morphology and with [[LVEF]] ≤35% despite [[optimal medical therapy]] in order to improve symptoms and reduce [[morbidity]] and [[mortality]]<br> | |||
|- | |- | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''([[ESC guidelines classification scheme|Class III, Level of Evidence A]]) :''' | ||
|- | |- | ||
| | |style="padding: 0 5px; font-size: 100%; background: #F5F5F5; width: 70%" align=left| | ||
❑[[CRT]] is not recommended in [[patients]] with a [[QRS]] duration <130 ms who do not have an indication for pacing due to [[high degree AV block]]<br> | |||
|} | |} | ||
{| | |||
! colspan="2" style="background: PapayaWhip;" align="center" + |The above table adopted from 2021 ESC Guideline | |||
|- | |||
|}<ref name="pmid34447992">{{cite journal |vauthors=McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A |title=2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure |journal=Eur Heart J |volume=42 |issue=36 |pages=3599–3726 |date=September 2021 |pmid=34447992 |doi=10.1093/eurheartj/ehab368 |url=}}</ref> | |||
{| | ===[[Cardiac resynchronization therapy]]=== | ||
|- | *[[CRT]] reduces [[morbidity]] and [[mortality]].<ref name="pmid26269413">{{cite journal |vauthors=Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR |title=Individual patient data network meta-analysis of mortality effects of implantable cardiac devices |journal=Heart |volume=101 |issue=22 |pages=1800–6 |date=November 2015 |pmid=26269413 |pmc=4680159 |doi=10.1136/heartjnl-2015-307634 |url=}}</ref> | ||
| | *[[CRT]] improves [[cardiac]] function, and enhances [[quality of life]]. | ||
|- | *Several characteristics predictors of improvement in [[morbidity]] and [[mortality]] including the extent of reverse remodelling as the most important mechanisms of action of [[CRT]]. | ||
| | * [[Patients]] with [[HFrEF]] and [[ischemic]] etiology have less improvement in [[LV ]] function due to [[myocardial]] scar tissue, which is less likely to undergo favorable remodelling. | ||
*[[Women]] may be more likely to respond to [[CRT]] than [[men]], possibly due to smaller body and [[heart]] size.<ref name="pmid26269413">{{cite journal |vauthors=Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR |title=Individual patient data network meta-analysis of mortality effects of implantable cardiac devices |journal=Heart |volume=101 |issue=22 |pages=1800–6 |date=November 2015 |pmid=26269413 |pmc=4680159 |doi=10.1136/heartjnl-2015-307634 |url=}}</ref> | |||
* [[QRS]] duration predicts [[CRT]] response.<ref name="pmid19723701">{{cite journal |vauthors=Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W |title=Cardiac-resynchronization therapy for the prevention of heart-failure events |journal=N Engl J Med |volume=361 |issue=14 |pages=1329–38 |date=October 2009 |pmid=19723701 |doi=10.1056/NEJMoa0906431 |url=}}</ref> | |||
* [[QRS]] morphology is related to a beneficial response to [[CRT]]. | |||
* [[Patients]] with [[left bundle branch block]] ([[LBBB]]) morphology are more likely to respond favorably to [[CRT]], whereas there is less certainty about [[patients]] with non-[[LBBB]] [[morphology]]. | |||
* [[Patients]] with [[LBBB]] morphology often have wider [[QRS]] durations, and there is a current debate about whether [[QRS]] durations or [[QRS]] morphology is the | |||
the main [[predictor]] of a beneficial response to [[CRT]].<ref name="pmid23900696">{{cite journal |vauthors=Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS |title=An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure |journal=Eur Heart J |volume=34 |issue=46 |pages=3547–56 |date=December 2013 |pmid=23900696 |pmc=3855551 |doi=10.1093/eurheartj/eht290 |url=}}</ref> | |||
* there is little evidence to suggest that [[QRS]] morphology or etiology of disease influence the effect of [[CRT]] on [[morbidity]] or [[mortality]]. | |||
* Implantation of [[CRT]] is not recommended if [[QRS]] duration is <130 ms. | |||
*If a [[patient]] is selected to receive an [[ICD]] and is in [[sinus rhythm]], with a [[LBBB]], [[CRT-D ]] should be considered if the [[QRS]] is between 130 and 149 ms and is recommended if QRS is ≥ 150 ms. | |||
* When [[LVEF]] is reduced, [[RV]] pacing may exacerbate [[cardiac dyssynchrony]]. | |||
* This can be prevented by [[CRT]], which might improve [[patient]] [[outcomes]]. | |||
* [[CRT]] rather than [[RV]] pacing is recommended for [[patients]] with [[HFrEF]] regardless of [[NYHA]] class who have an indication for [[ventricular]] pacing in order to reduce [[morbidity]], although no clear effect on [[mortality]] was observed. | |||
* In [[patients]] with [[HFrEF]] who have received a conventional [[pacemaker]] or an [[ICD]] and subsequently develop worsening [[HF]] with a high proportion of [[RV]] pacing, [[CRT]] implantation is recommended.<ref name="pmid23614585">{{cite journal |vauthors=Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS |title=Biventricular pacing for atrioventricular block and systolic dysfunction |journal=N Engl J Med |volume=368 |issue=17 |pages=1585–93 |date=April 2013 |pmid=23614585 |doi=10.1056/NEJMoa1210356 |url=}}</ref> | |||
* [[CRT]] is superior to [[RV]] pacing in [[patients]] undergoing [[atrioventricular]] ([[AV]]) [[node]] [[ablation]] in [[AF]] [[patients]].<ref name="pmid21606084">{{cite journal |vauthors=Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C |title=Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial |journal=Eur Heart J |volume=32 |issue=19 |pages=2420–9 |date=October 2011 |pmid=21606084 |doi=10.1093/eurheartj/ehr162 |url=}}</ref> | |||
* In [[patients]] with [[AF]], [[ CRT-D]] compared with [[ICD]], was not benefit and less than half of [[patients]] had >90% [[biventricular capture]]. | |||
* [[CRT]] in [[patients]] with [[AF]] may be an option in selected patient with [[QRS]]≥ 150 ms, high [[biventricular pacing]].<ref name="pmid12419298">{{cite journal |vauthors=Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P, Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC |title=Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation |journal=Eur Heart J |volume=23 |issue=22 |pages=1780–7 |date=November 2002 |pmid=12419298 |doi=10.1053/euhj.2002.3232 |url=}}</ref> | |||
*When [[biventricular capture]] is <98%, it reflects a loss of resynchronization and poor [[prognosis]] in [[CRT]]. | |||
* [[ Patients]] with extensive [[myocardial]] scar will have less improvement in [[LV]] function with [[CRT]]. | |||
* [[Pacing]] thresholds are higher in scarred [[myocardium]] and, if possible, lead placement should avoid such regions. | |||
*Although [[patients]] with extensive [[scarring]] have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from [[CRT]]. | |||
* Optimization of [[AV intervals]] or [[interventricular delay intervals]] ([[VV intervals]]) after implantation by using [[echo]]- or [[electrocardiographic]] criteria or [[BP]] response may be considered for [[patients]] who have had no response to [[CRT]].<ref name="pmid23900696">{{cite journal |vauthors=Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS |title=An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure |journal=Eur Heart J |volume=34 |issue=46 |pages=3547–56 |date=December 2013 |pmid=23900696 |pmc=3855551 |doi=10.1093/eurheartj/eht290 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Cardiology]] | |||
Latest revision as of 11:43, 25 February 2022
|
Cardiac resynchronization therapy Microchapters |
|
Treatment |
|---|
|
Cardiac resynchronization therapy indications On the Web |
|
American Roentgen Ray Society Images of Cardiac resynchronization therapy indications |
|
Directions to Hospitals Administering Cardiac resynchronization therapy |
|
Risk calculators and risk factors for Cardiac resynchronization therapy indications |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Sara Zand, M.D.[2] Bhaskar Purushottam, M.D. [3], Hardik Patel, M.D.
Overview
Cardiac resynchronization therapy (CRT) with or without an implantable cardiac defibrillator (ICD) is indicated in patients who have an LVEF less than or equal to 35%, left bundle branch block (LBBB) with a QRS duration greater than or equal to 0.15 seconds, and normal sinus rhythm, for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms in patients whose medical therapy has been optimized.
Indications
2021 ESC Guideline for Cardiac Resynchronization Therapy implantation
Abbreviations:
AF: Atrial fibrillation;
A-V: Atrio-ventricular;
CRT: Cardiac resynchronization therapy ;
HFrEF: Heart failure with reduced ejection fraction;
ICD: Implantable cardioverter-defibrillato;
LBBB:Left bundle branch block;
LVEF: Left ventricular ejection fraction;
NYHA:New York Heart Association;
RV: = Right ventricular
| Recommendations for cardiac resynchronization therapy implantation in patients with heart failure |
| (Class I, Level of Evidence A): |
|
❑ CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 ms and LBBB QRS morphology and with LVEF ≤35%
despite optimal medical therapy in order to improve symptoms and reduce morbidity and mortality |
| (Class IIa, Level of Evidence B): |
|
❑ CRT should be considered for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 ms and non-LBBB QRS morphology and
with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality |
| (Class IIb, Level of Evidence B) : |
|
❑ CRT may be considered for symptomatic patients with HF in sinus rhythm with a QRS duration of 130-149 ms and non-LBBB QRS morphology and with LVEF ≤35% despite optimal medical therapy in order to improve symptoms and reduce morbidity and mortality |
| (Class III, Level of Evidence A) : |
|
❑CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high degree AV block |
| The above table adopted from 2021 ESC Guideline |
|---|
Cardiac resynchronization therapy
- CRT reduces morbidity and mortality.[2]
- CRT improves cardiac function, and enhances quality of life.
- Several characteristics predictors of improvement in morbidity and mortality including the extent of reverse remodelling as the most important mechanisms of action of CRT.
- Patients with HFrEF and ischemic etiology have less improvement in LV function due to myocardial scar tissue, which is less likely to undergo favorable remodelling.
- Women may be more likely to respond to CRT than men, possibly due to smaller body and heart size.[2]
- QRS duration predicts CRT response.[3]
- QRS morphology is related to a beneficial response to CRT.
- Patients with left bundle branch block (LBBB) morphology are more likely to respond favorably to CRT, whereas there is less certainty about patients with non-LBBB morphology.
- Patients with LBBB morphology often have wider QRS durations, and there is a current debate about whether QRS durations or QRS morphology is the
the main predictor of a beneficial response to CRT.[4]
- there is little evidence to suggest that QRS morphology or etiology of disease influence the effect of CRT on morbidity or mortality.
- Implantation of CRT is not recommended if QRS duration is <130 ms.
- If a patient is selected to receive an ICD and is in sinus rhythm, with a LBBB, CRT-D should be considered if the QRS is between 130 and 149 ms and is recommended if QRS is ≥ 150 ms.
- When LVEF is reduced, RV pacing may exacerbate cardiac dyssynchrony.
- This can be prevented by CRT, which might improve patient outcomes.
- CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed.
- In patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, CRT implantation is recommended.[5]
- CRT is superior to RV pacing in patients undergoing atrioventricular (AV) node ablation in AF patients.[6]
- In patients with AF, CRT-D compared with ICD, was not benefit and less than half of patients had >90% biventricular capture.
- CRT in patients with AF may be an option in selected patient with QRS≥ 150 ms, high biventricular pacing.[7]
- When biventricular capture is <98%, it reflects a loss of resynchronization and poor prognosis in CRT.
- Patients with extensive myocardial scar will have less improvement in LV function with CRT.
- Pacing thresholds are higher in scarred myocardium and, if possible, lead placement should avoid such regions.
- Although patients with extensive scarring have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from CRT.
- Optimization of AV intervals or interventricular delay intervals (VV intervals) after implantation by using echo- or electrocardiographic criteria or BP response may be considered for patients who have had no response to CRT.[4]
References
- ↑ McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam C, Lyon AR, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F, Kathrine Skibelund A (September 2021). "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure". Eur Heart J. 42 (36): 3599–3726. doi:10.1093/eurheartj/ehab368. PMID 34447992 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ 2.0 2.1 Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR (November 2015). "Individual patient data network meta-analysis of mortality effects of implantable cardiac devices". Heart. 101 (22): 1800–6. doi:10.1136/heartjnl-2015-307634. PMC 4680159. PMID 26269413.
- ↑ Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W (October 2009). "Cardiac-resynchronization therapy for the prevention of heart-failure events". N Engl J Med. 361 (14): 1329–38. doi:10.1056/NEJMoa0906431. PMID 19723701.
- ↑ 4.0 4.1 Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS (December 2013). "An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure". Eur Heart J. 34 (46): 3547–56. doi:10.1093/eurheartj/eht290. PMC 3855551. PMID 23900696.
- ↑ Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS (April 2013). "Biventricular pacing for atrioventricular block and systolic dysfunction". N Engl J Med. 368 (17): 1585–93. doi:10.1056/NEJMoa1210356. PMID 23614585.
- ↑ Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, Luzi M, Tolosana JM, Navazio A, Menozzi C (October 2011). "Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial". Eur Heart J. 32 (19): 2420–9. doi:10.1093/eurheartj/ehr162. PMID 21606084.
- ↑ Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P, Mabo P, Levy T, Gadler F, Bailleul C, Daubert JC (November 2002). "Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation". Eur Heart J. 23 (22): 1780–7. doi:10.1053/euhj.2002.3232. PMID 12419298.